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HF and is considered one of key contraindica‑
tions to orthotopic heart transplant (OHT).2,9 
Reversing increased pulmonary capillary pres‑
sure represents a therapeutic challenge, which 
would make OHT—a final resolution of conges‑
tive HF—possible.
There have been few studies that analyzed 
the  impact of CF ‑LVAD implantation on pul‑
monary pressure and resistance. Some authors 
INTRODUCTION A  constant increase in 
the number of patients with end ‑stage heart fail‑
ure (HF) and a shortage of heart donors world‑
wide implies a wider use of mechanical circula‑
tory support, mainly continuous ‑flow left ven‑
tricular assist devices (CF ‑LVADs).1
Pulmonary hypertension (PH) due to in‑
creased pulmonary vascular resistance (PVR) 




















BACKGROUND An increasing number of patients with end ‑stage heart failure implies a wider use of left 
ventricular assist devices (LVADs). Irreversible pulmonary hypertension (PH) is a predictor of unfavorable 
prognosis and a contraindication to orthotopic heart transplant (OHT).
AIMS The aim of this study was to evaluate the effect of continuous ‑flow LVAD (CF ‑LVAD) support on 
pulmonary pressure and pulmonary vascular resistance (PVR) as well as the impact of pre ‑LVAD hemodynamic 
parameters on survival during LVAD support.
METHODS Data collected from 106 patients who underwent CF ‑LVAD implantation in the years 2009 to 
2018 (men, 95.3%; mean [SD] age, 51.8 [12] years; mean [SD] INTERMACS profile, 2.9 [1.6]; mean [SD] 
LVAD support time, 661 [520] days; follow ‑up until May 2019) were retrospectively analyzed.
RESULTS Right heart catheterization was performed before LVAD implantation in 94 patients (88.7%), after 
implantation—in 31 (29.2%), and before and after implantation—in 28 (26.4%). We observed mean 
pulmonary artery pressure (mPAP) >25 mm Hg in 65 patients (61.3%) and PVR >2.5 Wood units in 33 patients 
(31.1%) before LVAD implantation. A significant improvement after CF ‑LVAD implantation was noted in mPAP, 
pulmonary capillary wedge pressure, transpulmonary gradient, PVR, cardiac output (P <0.001 for all 
parameters), and cardiac index (P = 0.003). All patients with initially irreversible PH became eligible for OHT 
during LVAD support. Survival during LVAD support did not depend on initial mPAP and PVR.
CONCLUSIONS In patients with end ‑stage heart failure, CF ‑LVAD support leads to a significant reduction 
of pre‑ and postcapillary PH. Survival on CF ‑LVAD support is independent of elevated mPAP and PVR 
before implantation, which suggests that LVADs decrease the risk associated with PH.
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performed before LVAD implantation, the last 
measurements were analyzed. In the case of sev‑
eral post ‑LVAD measurements, the last one was 
taken into consideration. In view of national reg‑
ulations, bridge therapy to OHT or bridge thera‑
py to candidacy was the only strategy to implant 
CF ‑LVADs, which was allowed and used.
Out of 106 study patients (patient demograph‑
ic data are shown in Supplementary material, Ta-
ble S1), data on baseline RHC at the time of el‑
igibility evaluation for OHT or mechanical cir‑
culatory support were available in 95 patients 
(89.6%) and in 31 (29.2%) after CF ‑LVAD im‑
plantation. In 11 patients before LVAD implan‑
tation, RHC was either not performed due to se‑
vere illness at implantation (Interagency Regis‑
try of Mechanically Assisted Circulatory Support 
[INTERMACS] profile 1) or performed outside 
our institution and data on patient outcomes 
were therefore unavailable. A single patient in 
the preimplantation group was excluded from 
the analysis, because the reversibility test was 
not performed according to standard protocols. 
Post ‑LVAD hemodynamic measurements were 
obtained in patients who had no other contra‑
indications to OHT. All available pre‑ and post‑
‑LVAD hemodynamic measurements are shown 
in Supplementary material, Table S2.
The study population was divided according 
to RHC performed and its timing in reference 
to CF ‑LVAD implantation, with a special focus 
on the selected group of 28 patients who had 
complete pre‑ and post ‑LVAD RHC measure‑
ments performed (FIGURE 1). Eleven (39.2%) and 
36 (38.3%) patients before LVAD implantation 
in the groups of 28 and 94 patients, respectively, 
and a single patient with severe right ventricu‑
lar failure after CF ‑LVAD implantation had RHC 
performed being supported with inotropes be‑
cause of catecholamine dependence.
In the next step, we analyzed the impact of 
mean pulmonary artery pressure (mPAP) higher 
than 25 mm Hg and PVR above 2.5 Wood units 
on survival during CF ‑LVAD support. These 
thresholds were chosen above the borderline 
value of mPAP, according to the European So‑
ciety of Cardiology guidelines, similarly as in 
the studies by Mikus et al11 and Selim et al.6 If 
PVR surpassed 2.5 Wood units, OHT was not 
performed in our institution, which is a remi‑
niscent of the Stanford initial experience, not 
in line with the current International Society 
for Heart and Lung Transplantation guidelines.
The study was approved by the appropriate 
ethics review board. Informed patient consent 
was not required owing to the retrospective data 
analysis.
Statistical analysis Statistical analysis was 
performed using the Stata 15 software (Stata‑
Corp LLC, College Station, Texas, United States). 
Baseline patient characteristics were expressed 
reported that these hemodynamic parameters 
significantly decreased as early as after 6 weeks 
of support, whereas others demonstrated that in‑
creased values persisted even after years of LVAD 
support.3 Also, measurement methods varied from 
standard right heart catheterization (RHC) to re‑
mote recording with the use of CardioMEMS.3‑6
The 2 key issues regarding the overall survival 
of patients with PH bridged with CF ‑LVAD are:
1	 Can CF ‑LVADs significantly and effective‑
ly lower elevated pulmonary pressure and pul‑
monary vascular resistance to make patients el‑
igible for OHT?
2	 Is pre ‑LVAD PH associated with negative 
prognosis during CF ‑LVAD support?
We address these issues in the present study.
METHODS The clinical and hemodynamic data 
of 106 patients implanted with CF ‑LVADs be‑
tween the years 2009 and 2018 (101 men [95.3%]; 
follow ‑up until May 2019) were collected and ret‑
rospectively analyzed (as part of the EUROMACS 
[European Registry for Patients with Mechanical 
Circulatory Support] study). The study patients 
were censored at the end of care in our institu‑
tion (1 patient), at OHT, at pump explantation 
due to heart regeneration, or death.
Patients with end ‑stage HF were evaluated for 
eligibility for CF ‑LVAD implantation according to 
the European and American guidelines. We ad‑
opted the definitions of pre‑ and postcapillary PH 
endorsed by the European Society of Cardiology.7,8
Hemodynamic measurements were performed 
using RHC via jugular or femoral vein access. 
Cardiac output was measured using thermodi‑
lution before and after LVAD implantation. In 
stable patients with PH and PVR higher than 2.5 
Wood units, provided that sufficient systolic sys‑
temic arterial pressure was observed, a revers‑
ibility test was performed after the intravenous 
administration of sodium nitroprusside at in‑
creasing doses, according to the Polish and Stan‑
ford protocols.9,10 If several RHC procedures were 
WHAT’S NEW?
Due to an epidemic of heart failure (HF), the number of patients suffering from 
end ‑stage HF is also on the rise. In this population, optimal medical treatment 
often remains insufficient. In view of the shortage of heart donors, it results in 
a wider use of mechanical circulatory support—nowadays, mostly continuous ‑flow 
left ventricular assist devices (CF ‑LVADs). Among numerous benefits these devices 
could offer patients with end ‑stage HF, they can help restore eligibility for heart 
transplant in the case of irreversible pulmonary hypertension if a sufficient decrease 
in pulmonary pressure and pulmonary vascular resistance is achieved. This study 
shows a significant reduction of pre‑ and postcapillary hypertension after CF ‑LVAD 
implantation and not reduced survival rates in patients receiving CF ‑LVAD support, 
regardless of the initially elevated pulmonary pressure and pulmonary vascular 
resistance. Our study findings also contribute to establishing the optimal pulmonary 
pressure surveillance in patients awaiting heart transplant in whom CF ‑LVADs are 
used as a bridge therapy.
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RESULTS In a selected group of 28 patients 
in whom complete data on RHC before and af‑
ter CF ‑LVAD implantation were available, 19 
patients (67.9%) had the HeartWare device im‑
planted, 5 (17.9%) HeartMate 3, and 4 (14.3%) 
HeartMate 2. The mean (SD) time of RHC was 
106 (203) days (median [IQR], 28 [9–107] days) 
before and 622 (416) days (median [IQR], 521 
[396–736] days) after CF ‑LVAD implantation. 
as percentages for categorical variables and mean 
(SD) and median (interquartile range [IQR]) for 
continuous variables. The univariable compari‑
son of categorical variables was performed using 
the 1‑sided Fisher exact test. Survival was esti‑
mated by the Kaplan–Meier method. Log ‑rank 
tests were used to compare the study groups. All 
reported values were 1‑tailed, and a P value less 
than 0.05 was considered significant.
TABLE 1	 Characteristics	of	the	study	patients	before	left	ventricular	assist	device	implantation	(n	=	28)
Characteristic Patients,	n	(%)
Ischemic etiology of HF 13 (46.4)
Dilated cardiomyopathy 11 (39.3)
History of infection before HF symptoms 2 (7.1)
Inotropes at LVAD implantation 18 (64.3)
Diabetes 10 (35.7)
Arterial hypertension 10 (35.7)
Chronic kidney disease—stage 3 or higher 15 (53.6)
Chronic obstructive pulmonary disease / obstructive sleep apnea syndrome 0
Atrial fibrillation / flutter 18 (64.3)
History of ischemic stroke 3 (10.7)







Abbreviations: CF ‑LVAD, continuous ‑flow left ventricular assist device; HF, heart failure; INTERMACS, Interagency Registry of 
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FIGURE 1 Right heart 
catheterization (RHC) in 
patients before and after 
continuous­‑flow­left­
ventricular assist device 
(CF ‑LVAD) implantation
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Vasoreactivity testing Before LVAD im‑
plantation, 8 individuals in the group of 28 pa‑
tients (28.6%) and 14 in the group of 94 patients 
(14.9%) with PVR higher than 2.5 Wood units 
had undergone a pulmonary artery pressure re‑
versibility test. In the selected group of 28 pa‑
tients, reversible PH was noted in 5 patients 
and a fixed form of the disease in 3 patients. In 
the group of 94 patients, these conditions were 
seen in 10 and 4 patients, respectively.
Indications for vasoreactivity testing were es‑
tablished according to the Polish recommenda‑
tions on the hemodynamic assessment of pul‑
monary circulation.10 No reversibility tests were 
performed in patients after CF ‑LVAD implanta‑
tion owing to a sufficient decrease in pulmonary 
pressure and pulmonary vascular resistance.
The impact of continuous ‑flow left ventricular 
assist device support on hemodynamic mea-
surements We compared hemodynamic mea‑
surements obtained in 28 patients (26.4%) who 
had RHC performed before and after LVAD im‑
plantation. A significant improvement after LVAD 
implantation was observed in mPAP, pulmonary 
capillary wedge pressure, transpulmonary gradi‑
ent, PVR, cardiac output, and cardiac index (TABLE 2). 
Data on pharmacological therapy before and after 
CF ‑LVAD implantation are shown in TABLE 3.
Next, we examined the impact of pre ‑LVAD 
mPAP and PVR on survival during CF ‑LVAD sup‑
port in the whole study group in which RHC was 
performed before LVAD implantation and, ad‑
ditionally, in the selected group of 28 patients.
Out of 94 patients, 65 (69.1%) had pulmo‑
nary hypertension with mPAP higher than 
25 mm Hg, and 33 patients (35.1%) had PVR 
above 2.5 Wood units before LVAD implanta‑
tion. Sixty seven patients (71.2%) had postcap‑
illary PH with pulmonary capillary wedge pres‑
sure higher than 15 mm Hg at the pre ‑LVAD he‑
modynamic measurement.
Survival probability depending on the presence 
of initial (pre ‑LVAD) PH with mPAP higher than 
25 mm Hg and increased PVR above 2.5 Wood 
units was analyzed using a log ‑rank test and no 
significant differences were found (FIGURE 4 and 
FIGURE 5; Supplementary material, Figures S1 and S2).
None of the study patients had PVR above 
2.5 Wood units (the biggest value was 2.5 Wood 
units) and only a single patient had mPAP high‑
er than 25 mm Hg (27 mm Hg) during CF ‑LVAD 
support. In our study, all patients with fixed pre‑
‑LVAD PH who had undergone RHC after LVAD 
implantation became eligible for OHT.
DISCUSSION Used as a bridge therapy to can‑
didacy, CF ‑LVADs seem to offer benefit, result‑
ing not only in improved quality of life but also 
in the restored eligibility for OHT, especially in 
patients with fixed postcapillary PH.
The mean (SD) CF ‑LVAD support duration was 
1041 (555) days (range, 65–2068 days).
In this study group, the mean (SD) age at CF‑
‑LVAD implantation was 53.3 (9) years (range, 
26.9–66.2 years). Further clinical preimplanta‑
tion characteristics are reported in TABLE 1.
Data on overall survival during CF ‑LVAD sup‑
port according to the Kaplan–Meier analysis 
for the whole cohort and the selected group of 
28 patients are depicted in FIGURES 2 and 3. Heart 
transplant rates in those groups were 29.2% (31 
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support. This might suggest that a longer LVAD 
support is necessary to achieve a sufficient reduc‑
tion in PH. Also, our findings could be attribut‑
ed to the up titration of drugs such as β‑blockers, 
angiotensin‑converting enzyme inhibitors, an‑
giotensin II receptor blockers, spironolactone, or 
eplerenone and a high rate of sildenafil use (89.2%) 
in our cohort after LVAD implantation. The use 
of pulmonary vasodilators in patients with HF 
including those with LVADs has been extensive‑
ly studied, especially in patients with right ven‑
tricular failure, and a beneficial effect of sildenafil 
was noted, which is consistent with our findings.15
In a recent study, Ruan et al16 reported PVR 
stabilization after 6 months of LVAD support, 
particularly in patients with PVR lower than or 
equal to 3 Wood units. The results of our study 
also suggest that, under proper medical treat‑
ment, strict pulmonary pressure surveillance 
during CF ‑LVAD support may not be necessary 
owing to a sufficient decrease in PH achieved 
with LVADs.16 Another recent study by Ando  et 
al17 showed no significant differences in survival 
rates depending on pre ‑LVAD PVR, which is con‑
sistent with our findings. Of note, in a study by 
Schumer et al,18 the authors emphasized the key 
Our study showed that CF ‑LVAD support 
successfully reduces PH, and elevated pulmo‑
nary pressure and PVR measured before LVAD 
implantation do not worsen survival during 
LVAD support.
In the whole CF ‑LVAD cohort, we observed 
survival rates similar to those reported in inter‑
national registries, whereas the selected group 
of 28 patients achieved much higher surviv‑
al rates in the first 2 years of LVAD support.12,13 
This could result from the fact that these pa‑
tients survived the perioperative period and 
the time of CF ‑LVAD support without any seri‑
ous complications and remained candidates for 
OHT. The results of the present study are in line 
with those reported by Tsiouris et al,3 Zimpfer 
et al,4 Selim et al,6 and Mikus et al,11 yet in con‑
trary to recent studies on the use of CardioMEMS, 
in which 75% of the study patients maintained 
high mPAP during CF ‑LVAD support.5 In all our 
patients who underwent RHC after CF ‑LVAD im‑
plantation, PVR decreased at least to 2.5 Wood 
units. A significant decrease in pulmonary pres‑
sure and PVR in a bigger fraction of patients in 
our study could be due to the fact that RHC was 
performed after a much longer time of CF ‑LVAD 
TABLE 2	 Hemodynamic	measurements	before	and	after	continuous-flow	left	ventricular	assist	device	
implantation	in	28	study	patients
Parameter Before	LVAD	implantation After	LVAD	implantation P value
mPAP, mm Hg 32.1 (10); 16–49 17.8 (4.2); 10–27 <0.001
PCWP, mm Hg 20 (8.1); 9–39 10.8 (5); 4–27 <0.001
TPG, mm Hg 12.1 (5.7); 5–26 7.6 (2.5); 2–12 <0.001
PVR, Wood units 3.3 (2.2); 0.9–10 1.5 (0.5); 0.4–2.5 <0.001
CO, l/min 4.2 (1.2); 2.1–7.8 5.2 (1.2); 2.8–8.4 <0.001
CI, l/min/m2 2.2 (0.6); 1.2–3.7 2.6 (0.5); 1.5–4 0.004
Data are presented as mean (SD); range.
Abbreviations: CI, cardiac index; CO, cardiac output; mPAP, mean pulmonary artery pressure; PCWP, pulmonary capillary wedge 




Loop diuretics 82.1 64.3
Spironolactone / eplerenone 82.1 96.4
β ‑Blocker 53.6 100




Data are presented as the percentage of patients.
Abbreviations: ACEI, angiotensin ‑converting enzyme inhibitor; ARB, angiotensin II receptor blocker; others, see TABLE 1
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by Tsukashita et al,19 PVR above 5 Wood units 
after LVAD implantation was a strong predic‑
tor of early mortality after OHT, which tripled 
the risk of death compared with the low‑PVR 
group. In that study, the number of patients with 
high PVR during LVAD support increased after 
OHT and, then, gradually decreased over time. 
This may suggest that hemodynamic measure‑
ments taken during LVAD support do not ful‑
ly reflect pulmonary pressure after OHT in pa‑
tients formerly bridged with LVADs, although 
the values generally improve during post ‑OHT 
follow ‑up. Currently, RHC performed on an on‑
going LVAD support, which has been widely used 
in various centers, still seems to remain the lead‑
ing method of pulmonary pressure assessment 
before OHT, although it has some limitations. It 
is possible that hemodynamic parameters mea‑
sured during LVAD support may not fully re‑
flect true values and would be more reliable af‑
ter stopping the pump, as it is sometimes done 
when pump explantation is considered owing 
to heart regeneration. However, this procedure 
carries a thrombotic risk and might therefore 
be unsuitable for routine use.21
In next studies including patients bridged 
with CF ‑LVADs, we will follow changes in pulmo‑
nary pressure after OHT to evaluate if PH revers‑
ibility is durable and to explore the association 
between pre ‑LVAD hemodynamic parameters 
and post ‑transplant survival rates. Developing 
a CF ‑LVAD‑dedicated risk scale including hemo‑
dynamic, clinical, and biochemical factors—pre‑
dictors of survival, could also be helpful in de‑
termining an optimal time frame for OHT dur‑
ing LVAD support, as it has been explored in 
some studies of non ‑LVAD patients with end‑
stage HF who awaited OHT.22,23
Study limitations Our study had some lim‑
itations owing to its retrospective design. In 
several patients, data were missing, including 
information on RHC before implantation. Fur‑
thermore, RHC was not performed in all pa‑
tients before and after CF ‑LVAD implantation 
at previously set and standardized time points. 
As hemodynamic measurements were taken 
at various times before and after LVAD implan‑
tation, we cannot exclude that, in some cases, 
patients’ hemodynamic parameters would be 
different when taken at another time point. 
Also, patients who died and had never had pul‑
monary pressure controlled could have had per‑
sistent PH despite CF ‑LVAD support. In our 
study, over 1/3 of the patients received cate‑
cholamines at the time of RHC measurement 
because of inotrope dependence. Though, we 
cannot exclude that pulmonary hemodynam‑
ic values would have been different when mea‑
sured without inotropic support. However, it 
was the only possibility to measure pulmo‑
nary pressure and resistance in this group of 
aspect of PH reversibility by showing that PH 
resolution during CF ‑LVAD support improved 
post ‑transplant survival.18
In some studies, pulmonary pressure was 
also assessed after OHT in patients previously 
bridged with LVADs and persistent PH after OHT 
was found in some of them.19 Post ‑transplant 
survival depending on pre ‑and post‑LVAD im‑
plantation pulmonary pressure and resistance 

















65 54 42 22 9 4 2
mPAP >25 mm Hg
29 25 21 13 10 6 2
mPAP ≤25 mm Hg
Patients at risk, n
Time on LVAD support, mo
mPAP ≤25 mm Hg
mPAP >25 mm Hg
0 6 12 24 36 48 60
FIGURE 4­ Survival­probability­during­continuous­‑flow­left­ventricular­assist­device­(CF‑LVAD)­
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support depending on pre ‑LVAD pulmonary vascular resistance (PVR) in 94 study patients











































inotrope ‑dependent patients, which enabled 
us to qualify them for OHT following a suffi‑
cient decrease of PH.
Conclusions In conclusion, CF ‑LVAD implan‑
tation decreases the fluid overload of the pulmo‑
nary vascular bed, leading to a significant reduc‑
tion of pulmonary pressure and resistance. This 
allows for heart transplant in patients with a 
history of pre‑ and post capillary PH. There are 
no significant differences in survival during CF‑
‑LVAD support depending on the presence of PH 
(at mPAP >25 mm Hg) and increased vascular re‑
sistance (PVR >2.5 Wood units) before LVAD im‑
plantation, which suggests that CF‑LVADs reduce 
the risk associated with PH. Further research is 
needed to establish an optimal pulmonary pres‑
sure surveillance protocol in patients bridged 
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